288 related articles for article (PubMed ID: 37033238)
1. Cancer-related hypercalcemia and potential treatments.
Almuradova E; Cicin I
Front Endocrinol (Lausanne); 2023; 14():1039490. PubMed ID: 37033238
[TBL] [Abstract][Full Text] [Related]
2. [The significance of early diagnosis of cancer-related hypercalcaemia].
Radványi I; Csikós A; Balogh S
Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
5. [Hypercalcemia].
Dylewska M; Wieliczko M
Wiad Lek; 2013; 66(4):307-10. PubMed ID: 24490483
[TBL] [Abstract][Full Text] [Related]
6. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
Rosner MH; Dalkin AC
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
9. The management of hypercalcaemia in advanced cancer.
Pettifer A; Grant S
Int J Palliat Nurs; 2013 Jul; 19(7):327-31. PubMed ID: 24273809
[TBL] [Abstract][Full Text] [Related]
10. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
11. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy.
Sheehan MT; Wermers RA; Jatoi A; Loprinzi CL; Onitilo AA
Med Hypotheses; 2020 Oct; 143():110149. PubMed ID: 32763659
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia of malignancy: pathophysiology, diagnosis and treatment.
Mosekilde L; Eriksen EF; Charles P
Crit Rev Oncol Hematol; 1991; 11(1):1-27. PubMed ID: 1883526
[TBL] [Abstract][Full Text] [Related]
13. Refractory hypercalcemia of malignancy: a problem with many potential roots.
Farooki A
Front Endocrinol (Lausanne); 2023; 14():1088984. PubMed ID: 37265703
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcemia of Malignancy.
Hu MI
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
[TBL] [Abstract][Full Text] [Related]
15. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and management of severe hypercalcemia.
Nussbaum SR
Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
18. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
Farias ML
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
[TBL] [Abstract][Full Text] [Related]
19. [Tumor-induced hypercalcemia].
Hopfer O; Gawliczek A; Kiehl MG
Internist (Berl); 2013 Sep; 54(9):1043-50. PubMed ID: 23934479
[TBL] [Abstract][Full Text] [Related]
20. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
